POPS RICHARD F 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Mar 12, 2024
Insider Transaction Report
Form 4
POPS RICHARD F
Director
Transactions
- Exercise/Conversion
Non-Qualified Stock Option
2024-03-11$42.76/sh−100$4,276→ 23,200 totalExercise: $42.76Exp: 2025-05-28→ Common Stock (100 underlying) - Exercise/Conversion
Common Stock
2024-03-08$42.76/sh+1,700$72,692→ 31,212 total - Sale
Common Stock
2024-03-08$140.05/sh−1,700$238,078→ 29,512 total - Exercise/Conversion
Common Stock
2024-03-11$42.76/sh+100$4,276→ 29,612 total - Sale
Common Stock
2024-03-11$140.00/sh−100$14,000→ 29,512 total - Exercise/Conversion
Non-Qualified Stock Option
2024-03-08$42.76/sh−1,700$72,692→ 23,300 totalExercise: $42.76Exp: 2025-05-28→ Common Stock (1,700 underlying)
Footnotes (3)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 21, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025.